V. Mak

发表

Polymorphisms in apolipoprotein E and apolipoprotein A-V do not influence the lipid response to rosuvastatin but are associated with baseline lipid levels in Chinese patients with hyperlipidemia.

B. Tomlinson, Miao Hu, V. Mak, 2012, Journal of clinical lipidology.

Comments on “CYP3AP1*3 Allele Is Associated With Lipid‐Lowering Efficacy of Simvastatin and Atorvastatin in Chinese Women”

B. Tomlinson, Miao Hu, V. Mak, 2012, Journal of clinical pharmacology.

Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia

B. Tomlinson, Miao Hu, V. Mak, 2012, Pharmacogenetics and genomics.

The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins

K. To, B. Tomlinson, Miao Hu, 2011, Expert opinion on drug metabolism & toxicology.

Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients

B. Tomlinson, L. Baum, V. Lee, 2010, Pharmacogenetics and genomics.

Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin.

B. Tomlinson, O. Yin, Miao Hu, 2013, Drug metabolism and pharmacokinetics.

Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease

M. Waye, B. Tomlinson, Miao Hu, 2009 .

Simvastatin‐induced myopathy, the role of interaction with diltiazem and genetic predisposition

B. Tomlinson, M. Hu, V. Mak, 2011, Journal of clinical pharmacy and therapeutics.

Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects

B. Tomlinson, M. Chow, O. Yin, 2012, European Journal of Clinical Pharmacology.

Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily).

B. Tomlinson, Miao Hu, V. Mak, 2010, The American journal of cardiology.

Polymorphisms in apolipoprotein E and apolipoprotein A-V do not influence the lipid response to rosuvastatin but are associated with baseline lipid levels in Chinese patients with hyperlipidemia.

B. Tomlinson, Miao Hu, V. Mak, 2012, Journal of clinical lipidology.

Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients

B. Tomlinson, L. Baum, L. Tam, 2010, Pharmacogenetics and genomics.